Clinical Trials Browser

Phase 2 × NETWORK × Prostatic Neoplasms × Clear all

NCT03419234 2026-03-12

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

Phase 2 Active not recruiting

223 enrolled 14 charts

Prostatic Neoplasms

NCT02905318 2026-03-09

Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04597359 2026-03-02

To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04663997 2025-11-06

177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT02972060 2025-09-19

ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03385655 2025-08-21

Prostate Cancer Biomarker Enrichment and Treatment Selection

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT02788773 2025-05-15

Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer

Phase 2 Completed

52 enrolled 12 charts

Prostatic Neoplasms

NCT01309672 2025-02-26

S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy

Phase 2 Completed

41 enrolled 18 charts

Prostatic Neoplasms

NCT03869762 2024-09-25

DICE

Phase 2 Terminated

Neoplasm Metastasis, Prostatic Neoplasms

NCT01331083 2023-08-22

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Phase 2 Completed

68 enrolled 11 charts

Prostatic Neoplasms

NCT00093457 2023-08-04

Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms

NCT00258388 2023-08-04

Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

Phase 2 Completed

Prostatic Neoplasms

NCT01075308 2023-08-04

SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms

NCT01619813 2023-08-04

Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms

NCT00003871 2023-06-22

PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms

NCT00005847 2023-06-22

Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 2 Completed

Prostatic Neoplasms

NCT00003614 2023-06-15

Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms

NCT00771017 2023-05-25

Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer

Phase 2 Withdrawn

Prostatic Neoplasms

NCT00951535 2023-04-06

A Prospective Phase II Dose Escalation Study Using IMRT for High Risk N0 M0 Prostate Cancer. ICORG 08-17

Phase 2 Unknown

Prostatic Neoplasms

NCT02225704 2023-04-06

Radium-223 in Combination With Enzalutamide

Phase 2 Completed

Prostatic Neoplasms

NCT00450411 2022-06-21

Ultrasound-Guided Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer Previously Treated With External-Beam Radiation Therapy

Phase 2 Completed

100 enrolled 12 charts

Prostatic Neoplasms

NCT01434290 2022-06-09

Radiation Therapy in Treating Patients With Prostate Cancer

Phase 2 Completed

255 enrolled 15 charts

GenitourinaryOther

Prostatic Neoplasms, Radiation Injuries, Sexual Dysfunction, Physiological

NCT00006365 2020-10-22

External-Beam Radiation Therapy Plus Implanted Radiation Therapy in Treating Patients With Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms

NCT00091390 2020-08-10

Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer

Phase 2 Completed

129 enrolled 20 charts

Prostatic Neoplasms

NCT00025116 2020-04-06

ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 2 Completed

Prostatic Neoplasms

NCT00528866 2019-04-24

Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy

Phase 2 Completed

80 enrolled 11 charts

Prostatic Neoplasms

NCT00551525 2017-07-25

Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer

Phase 2 Completed

67 enrolled 10 charts

Prostatic Neoplasms

NCT01658527 2016-06-10

TAK-700 in Castration Resistant Prostate Cancer

Phase 2 Withdrawn

Neoplasm Metastasis, Prostatic Neoplasms

NCT00003312 2014-01-24

Brachytherapy in Treating Patients With Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms

NCT00685633 2013-08-20

Bicalutamide With or Without Enzastaurin in Treating Patients With Prostate Cancer

Phase 2 Withdrawn

Prostatic Neoplasms

NCT00028769 2013-07-16

S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer

Phase 2 Completed

41 enrolled 12 charts

Prostatic Neoplasms

NCT00433446 2013-02-05

S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 2 Completed

62 enrolled 13 charts

Prostatic Neoplasms

NCT00027794 2012-09-24

Radical Prostatectomy in Treating Patients With Locally Advanced Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms

NCT00085228 2012-09-24

Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate

Phase 2 Completed

Prostatic Neoplasms

NCT00027781 2012-07-24

MEN-10755 in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 2 Completed

Prostatic Neoplasms